Introduction {#S0001}
============

Glaucoma is the second-leading cause of blindness worldwide, and as the number of people affected by this disease continues to rise, it becomes an even more pressing public health problem.[@CIT0001],[@CIT0002] As severity increases, cost of care increases.[@CIT0003],[@CIT0004] Therefore, it is important glaucoma be treated early and effectively to halt disease progression and reduce the economic and personal burden on patients. The advent of minimally invasive glaucoma surgery (MIGS) and the plethora of options have provided an opportunity for safer interventional treatments earlier in the disease, and these procedures are often performed in combination with cataract surgery.[@CIT0005]

The iStent (Glaukos, San Clemente, CA, USA), the first US Food and Drug Administration--approved MIGS device, is a trabecular microbypass stent designed to bypass the trabecular meshwork to augment physiological outflow to Schlemm's canal and lower intraocular pressure (IOP).[@CIT0006] The safety and efficacy of the iStent alone,[@CIT0007]--[@CIT0009] as well as when combined with cataract surgery,[@CIT0010]--[@CIT0013] has been well established in the literature. Recently, a large study by Manoharan et al demonstrated that refractive surprise is more common in glaucoma patients having cataract surgery, in particular those with angle-closure and pseudoexfoliation glaucoma. It remains unclear whether this increased incidence of refractive surprise is secondary to ocular surface disease, an alteration of effective lens position, or other etiology.[@CIT0014] However, in subgroup analysis of cataract surgery combined with MIGS in primary open-angle glaucoma (OAG eyes) compared to nonglacuoma eyes, Manoharan et al did not find a significant difference in refractive surprise. Worth noting, this subgroup included eyes with microbypass stent, endoscopic cyclophotocoagulation (ECP), and both microbypass stent and ECP. To our knowledge, while the aforementioned study by Manoharan et al included a subset of eyes with combined iStent and phacoemulsification, this is the first study exclusively to study the refractive outcomes of combined iStent and phacoemulsification.

Previous studies have reported higher incidence of refractive surprise following cataract surgery in glaucoma patients compared to controls without glaucoma.[@CIT0014] Currently, there is substantial evidence showing that trabeculectomy is associated with significant with-the-rule astigmatic change, as well as increased refractive surprise.[@CIT0015]--[@CIT0020] Moreover, studies investigating both trabeculectomy and glaucoma-drainage devices, such as tube shunts, have found decreases in axial length, as well as a trend of more induced cylinder and more induced myopia,[@CIT0021]--[@CIT0023] suggesting that these more invasive glaucoma surgeries are not refractively neutral. However, Hammel et al investigated the impact of Ex-Press implant (Alcon, Fort Worth, TX, USA) surgery, and found that the transient increase in corneal astigmatism, both anterior and posterior, resolved by 3 months.[@CIT0024]

The limited research evaluating the impact of MIGS devices on refractive outcomes has been promising. Although the supraciliary microstent (CyPass; Alcon) is no longer available, due to long-term safety concerns, there was prior discussion regarding myopic shift associated with the device; however, a retrospective review presented by Flowers demonstrated no significant impact on refractive outcomes.[@CIT0025] To our knowledge, the impact of combined cataract surgery with trabecular microbypass--stent implantation on refractive outcomes has not yet been established. The present study aimed to investigate refractive outcomes after trabecular microbypass stent with combined cataract surgery in eyes with OAG.

Methods {#S0002}
=======

Study design {#S0002-S2001}
------------

This retrospective comparative study was comprised of a consecutive case series of patients undergoing combined cataract surgery and implantation of a trabecular microbypass stent from January 2017 to September 2017 compared to 50 patients having cataract surgery during the same time frame. All patients in the combined cataract surgery and trabecular microbypass--stent group had been diagnosed with mild--severe OAG. Stage of disease was based on visual field criteria and/or optic nerve--head changes, consistent with the American Academy of Ophthalmology Preferred Practice Pattern Guidelines.[@CIT0026] Gonioscopy was performed on each trabecular microbypass--stent patient to ensure adequate visualization of the angle for implantation of the device. The inclusion criterion in the combined cataract surgery and trabecular microbypass--stent group was the presence of OAG. There were no strict inclusion criteria for the cataract-surgery group, and 50 consecutive eyes were included. Eyes that were missing refractions were excluded. This study collected and evaluated data from procedures performed by the same surgeon (JPB) at a single site (Vance Thompson Vision, Sioux Falls, SD, USA), and was approved by the University of South Dakota Institutional Review Board. Informed consent was waived by the University of South Dakota, as all data collected were deidentified and included no more information than would normally be collected for this procedure.

Surgical technique {#S0002-S2002}
------------------

Cataract extraction was performed similarly in both groups with 2.4 mm temporal clear corneal incisions. In those receiving a trabecular microbypass stent, once the intraocular lens had been inserted, the microscope and patient's head were rotated approximately 30° away from the surgeon. With the nondominant hand, a gonioprism was held on the cornea and the trabecular meshwork brought into focus. With a preloaded injector, the trabecular microbypass stent was inserted through the clear corneal incision. The stent, on the tip of the inserter, was guided at a 20° angle into the trabecular meshwork and advanced inferiorly. The stent was released and the shaft of the insertion device used to push the heel of the device into the trabecular meshwork. Through "strumming" the device with the injector tip in a posterior-to-anterior direction, secure placement of the device was confirmed. The stent was repositioned if it had not been properly secured. In case where a region of pigmentation was noted on intraoperative gonioscopy, that region was targeted for placement.

Postoperative medications and follow-up {#S0002-S2003}
---------------------------------------

Postoperatively, patients were prescribed a drop regimen as follows: moxifloxacin 0.05% for 1 week, a daily NSAID (bromefenac 0.07% or nepafenac 0.3%) for 4 weeks, and a topical steroid (difluprednate 0.05% or prednisolone acetate 1%) for 4 weeks. The steroid therapy was initiated at four times per day and tapered to twice per day after 7 days. Patients kept on using their preoperative ocular hypotensive medications for at least 1 week or until the operating physician deemed the patient's IOP clinically acceptable. If there was progression of nerve-fiber loss on optical coherence tomography, progression of glaucomatous visual field loss, or a clinical judgment that the IOP level would likely cause either parameter to progress, postoperative medical therapy was escalated.

Outcome measurements {#S0002-S2004}
--------------------

The main outcome measures in the study were refractive outcomes, specifically the difference between target spherical equivalent (SE) and postsurgery SE between 1 and 3 months, as well as the difference in astigmatism pre- and postsurgery. Preoperative astigmatism was collected by dual-zone keratometry (Lenstar; Haag-Streit, Berne, Switzerland). Postoperative astigmatism was determined by manifest refraction. Intraocular lenses used in each of the two groups were recorded. Secondary outcome measures for the combined group included IOP and number of glaucoma medications. Notably, combination medications were reported as two medications. Preoperative IOP was obtained in the visit immediately prior to surgery and based on a single measure.

Preoperative data were used to establish a baseline, which typically occurred in the visit immediately before surgery. Postoperatively, data were collected from the following time points to compare with baseline data: 1 day, 1 week, 1 month, 3 months, and 6 months. At each time point, the data collected included IOP, number, and type of medications used, and manifest refraction was obtained at certain time points.

Statistical analyses {#S0002-S2005}
--------------------

XLStat version 2018.6 was used for statistical analyses. SE refractive outcome was calculated as the difference between the postoperative SE and target SE and divided into the percentage within 0.25 D, 0.50 D, and 1.00 D of the target. These results were compared to benchmark standards for refractive outcomes after cataract surgery, in addition to the cataract-only control group. A two one-sided test (TOST) equivalence test using upper and lower bounds of 0.25 (the smallest diopter unit able to be measured) was used to determine equivalence of SE outcomes between the combined and cataract-only surgery groups. Astigmatism outcomes were measured using American Society of Cataract and Refractive Surgery's Astigmatism Double Angle Plot Tool version 1.1.0.[@CIT0027] With this tool, preoperative corneal astigmatism is compared to postoperative refractive astigmatism. An independent *t*-test was used to compare astigmatism outcomes after the combined surgery to those after cataract surgery alone. A parametric paired *t*-test was used to determine the significance of the mean change in IOP from baseline to 1 month, 3 months, and 6 months. A parametric paired *t*-test was also used to determine the significance of the mean change in number of glaucoma medications from baseline to 1 month, 3 months, and 6 months. An *α*-level of 0.05 was considered statistically significant.

Results {#S0003}
=======

A total of 76 eyes from 43 patients with OAG who had had concomitant cataract surgery with microbypass stent were retrospectively analyzed, as were 50 eyes from 26 patients without OAG who had had only cataract surgery. Five of 81 eyes, or 6.2% of eyes, were excluded from the combined group on the basis of missing refractions. The mean age was 70.0 years for the cataract surgery with microbypass--stent group, with 47 female and 29 male subjects. The mean age was 70.4 years for the cataract-only group, with 39 female and 11 male subjects. Demographic data arepresented in [Table 1](#T0001){ref-type="table"}.Table 1Demographics for cataract + trabecular microbypass--stent group and cataract-only groupCataract + trabecular microbypass stentCataract onlyEyes, n7650Age (years)70.0370.42Female:male47:2939:11Open-angle glaucoma100%0 Severe5.3% Moderate13.2% Mild81.5%

SE outcomes were calculated using manifest refraction obtained between 1 and 3 months after surgery. In patients with concomitant cataract surgery with trabecular microbypass stent (n=76), 46% (35 of 76) had SEs within 0.25 D, 80% (61 of 76) had SEs within 0.50 D, and 95% (72 of 76) had SEs within 1.00 D of the target. In the control group (cataract extraction only), refractive outcomes between 1 and 3 months (n=50) were 52% (25 of 50) of patients with SEs within 0.25 D, 80% (40 of 50) with SEs within 0.50 D, and 94% (47 of 50) with SEs within 1.00 D of the target. These results are shown in [Figure 1](#F0001){ref-type="fig"}. A TOST equivalence test showed that the two groups had equivalent SE outcomes (t~124~4.5, *P*\<0.0001).Figure 1Difference between spherical equivalent outcome and target.**Notes:** Ratio of cases with spherical equivalent outcome within a certain number of designated diopters of target spherical equivalent. Blue bars represent cataract-only cases. Orange bars represent cases of cataract surgery with trabecular microbypass stent. TOST equivalence testing showed the spherical outcomes of the two groups were equivalent (*t*~124~=4.5, *P*\<0.0001).**Abbreviation:** TOST, two one-sided test.

The magnitude of preoperative corneal astigmatism and postoperative refractive astigmatism can be seen in [Figure 2](#F0002){ref-type="fig"} for the combined cataract and trabecular microbypass group and [Figure 3](#F0003){ref-type="fig"} for the cataract-only group. Preoperative and postoperative astigmatic vectors and their means and spread are illustrated in the double-angle plots in [Figures 4](#F0004){ref-type="fig"} and [5](#F0005){ref-type="fig"} for the combined-surgery and cataract-only surgery groups, respectively. For the combined surgery group, the preoperative centroid was 0.31 D at 90° ± 1.35 D and the mean absolute 1.14±0.78 D. The postoperative centroid was 0.08 D at 92° ± 1.05 D and the mean absolute 0.69±0.78 D. For the cataract surgery--only group, the preoperative centroid was 0.51 D at 96° ± 1.78 D and the mean absolute 0.82±1.63 D. The postoperative centroid was 0.22 D at 173° ± 1.12 D and the mean absolute 0.94±0.64 D. Comparison of the postoperative mean absolute of the combined-procedure group to the cataract-only group showed no significant difference in astigmatism outcome (*P*\>0.05). The distribution of different lens types (monofocal, multifocal, and toric) for each group is illustrated in [Figure 6](#F0006){ref-type="fig"}.Figure 2Magnitude of preoperative corneal astigmatism and postoperative refractive astigmatism in patients with combined cataract surgery with trabecular microbypass stent.Figure 3Magnitude of preoperative corneal astigmatism and postoperative refractive astigmatism in patients with cataract surgery only.Figure 4Double-angle plot showing preoperative and postoperative astigmatic vectors and their means and spread for the combined cataract surgery with trabecular microbypass--stent group.Figure 5Double-angle plot showing preoperative and postoperative astigmatic vectors and their means and spread for the cataract surgery--only group.Figure 6Distribution of different lens types (monofocal, multifocal, and toric) for the combined-surgery group and the cataract-only group.

In the OAG combined group, there was a significant IOP reduction at the 1-week, 1-month, 3-month, and 6-month time points compared to the preoperative baseline. Compared to a baseline mean of 18.7±5.8 mmHg, the mean IOP reduction was 2.0 mmHg (*P*\<0.05) at 1 week, 3.4 mmHg (*P*\<0.0001) at 1 month, 4.0 mmHg (*P*\<0.0001) at 3 months, and 3.4 mmHg (*P*\<0.01) at 6 months. These results are shown in [Figure 7](#F0007){ref-type="fig"}.Figure 7Mean intraocular pressure (IOP) and number of glaucoma medications from baseline to 6 months postoperatively in eyes implanted with a trabecular microbypass stent during cataract surgery.**Note:** Error bars represent SD.

In regard to hypotensive medication use in the OAG combined group, there was a statistically significant reduction at the 1-month, 3-month, and 6-month postoperative visits compared to the preoperative baseline. The preoperative baseline 1.3±1.2 was reduced by 0.4 (*P*\<0.05) at 1 month, 0.7 (*P*\<0.0001) at 3 months, and 0.9 (*P*\<0.01) at 6 months. These results are shown in [Figure 7](#F0007){ref-type="fig"}.

Discussion {#S0004}
==========

For glaucomatous treatment, numerous studies have established the safety and efficacy of the trabecular microbypass stent in combination with cataract surgery. This present study aimed to investigate the refractive impact of the trabecular microbypass stent. The results of this study produced similar refractive outcomes for cataract surgery combined with trabecular microbypass-- stent placement compared to cataract surgery alone. Between 1 and 3 months, 46% of patients had SEs within 0.25 D, 80% within 0.50 D, and 95% within 1.00 D of the target. These values exceed the benchmark standards set by the UK National Health Service of 55% within 0.50 D and 85% within 1.00 D.[@CIT0028],[@CIT0029] Additionally, these results meet the new benchmark of 94% within 1.00 D of the target proposed by Massachusetts Eye and Ear.[@CIT0030] In our study, the SE results at 1--3 months in the combined-procedure group were equivalent to those of cataract surgery alone.

For magnitude of astigmatism postoperatively between 1 to 3 months, 37% of patients were within 0.25 D, 51% within 0.50 D, 75% within 1.00 D, 87% within 1.50 D, and 89% within 2.00 D. While these results do suggest a trend of the combined procedure outperforming the cataract-only group in lower magnitude of astigmatism groupings, such as percentage within 0.25 D, overall analysis of astigmatism did not show a significant difference between the two groups. Additionally, both groups had similar distribution of intraocular lens types, suggesting that was not a confounding contributor in refractive outcomes.

Manoharan et al reported an increased incidence of refractive surprise following cataract surgery in glaucoma patients compared to controls: 40.3% vs 29.9% for \>0.50 D and 11.2% vs 4.9% for \>1.00 D, respectively.[@CIT0014] A subset of the glaucoma group in this study had combined cataract surgery and MIGS --- microbypass stent, ECP, or both microbypass stent and ECP --- and the results of this combined group were analyzed separately. In this subgroup analysis, Manoharan et al found a significant increase in refractive surprise in the combined cataract--MIGS group compared to cataract only in nonglaucoma eyes. Interestingly, when these data were analyzed further by glaucoma subtype, there was not a significant increase in refractive surprise in patients with primary OAG with the combined procedure, indicating the impact of glaucoma subtype on refractive outcome.[@CIT0014] Sheybani et al investigated the difference between predicted and actual refractive outcomes after combined cataract surgery and ECP in patients with OAG, and found that compared to OAG patients with phacoemulsification alone, combined cataract and ECP had more myopic outcomes than predicted and also had significantly increased variability in refractive outcomes.[@CIT0031] This work indicates that certain MIGS procedures could actually contribute to refractive surprise in OAG patients, which is something to recognize as new devices emerge in the space. The increased variability in outcomes and myopic shift with ECP shown by Sheybani et al suggests that the difference in refractive surprise found by Manoharan et al in the combined cataract--MIGS group (8.9%) compared to the nonglaucoma cataract group (4.9%), while not significant, could likely be even smaller if analysis for only combined cataract and microbypass stent was done and ECP results excluded. Indeed, our own results showed a refractive surprise \>1 D of 5% in the combined cataract and microbypass--stent group, which is comparable to both the nonglaucoma cataract-only group in Manoharan et al's study and our own nonglaucoma cataract-only group. Additionally, other reports have demonstrated the negative impact of more invasive glaucoma surgeries on astigmatism.[@CIT0020]--[@CIT0022]

However, the results of this study suggest that the combined procedure --- trabecular microbypass + cataract surgery --- is a favorable option in maintaining refractive outcomes similar to cataract surgery alone. Luebke et al similarly found that the combined procedure of cataract surgery with trabectomy, another MIGS procedure that uses electrocautery to permanently remove a portion of the trabecular meshwork and increase aqueous outflow, did not have significantly different refractive outcomes compared to cataract surgery alone.[@CIT0032] Our results add to the current growing body of literature showing minimal impact of MIGS devices on refractive outcome.[@CIT0024],[@CIT0025] The results of this study also add to the literature supporting the minimal surgical-induced astigmatism effect of cataract surgery combined with trabecular microbypass--stent insertion, showing no evidence of impaired refractive outcome with the combined procedure. Additionally, our study demonstrated a statistically significant drop in IOP and glaucoma medications consistent with previous studies evaluating the device.[@CIT0010]--[@CIT0013]

This study is not without limitations. The retrospective design of the study prevents uniform follow-up, which contributes to missing data at specific time points in the postoperative period, with some patients electing to follow up postoperatively at select time points, rather than all recommended standard time points used in the study. The control group consisted of 50 consecutive cases of cataract surgery alone during the same time period by the same surgeon, but was not matched in other ways. Notably, none of the control group patients had glaucoma. Additionally, the single IOP measure was a limitation in the secondary outcome analysis. Despite the limitations, this study contributes important data regarding combined cataract surgery with trabecular microbypass--stent placement. Future prospective studies with larger samples would be valuable for confirming that microbypass-stent placement at the same time of cataract surgery does not negatively impact refractive outcome. Indeed, given that traditionally patients with glaucoma who undergo cataract surgery alone have an increased incidence of refractive surprise, the combined procedure may result in refractive outcomes consistent with cataract surgery alone and concomitantly lower IOP.

To our knowledge, this is the first published report exclusively to evaluate refractive outcomes of cataract surgery combined with trabecular microbypass--stent implantation. The favorable findings of this study suggest the trabecular microbypass stent does not compromise refractive outcomes and can safely be combined with cataract surgery.

What was known {#S0005}
==============

MIGS devices are safe and are effective at lowering IOP.There is increased incidence of refractive surprise in glaucoma patients undergoing cataract surgery compared to those without glaucoma.

What this paper adds {#S0006}
====================

Combining trabecular microbypass--stent implantation with cataract surgery does not alter refractive outcomes in patients with OAG.The combined procedure achieves refractive outcomes on par with cataract surgery alone.
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